Navigation Links
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Date:12/29/2009

nts in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2008 and periodic reports filed with the Securities and Exchange Commission.

CONTACT:


    VIVUS, Inc.              Investor Relations:  The Trout Group
    Timothy E. Morris                             Brian Korb
    Chief Financial Officer                       646-378-2923
    650-934-5200

                             Media Relations:     Pure Communications, Inc.
                         
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Ill. , July 31, 2015 ... ® (NABP ® ) issued a report ... ensuring that action is taken against websites illegally ... Internet Drug Outlet Identification Program Progress Report ... , thousands of websites illegally distribute ...
(Date:7/31/2015)... 2015  Xcelience, a contract development and manufacturing ... a structured cash investment in Powdersize, a ... micronization and powder size classification within the pharmaceutical ... while simultaneously adding a complete set of particle ... "As we continue to build ...
(Date:7/31/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage biopharmaceutical ... autoimmune diseases, asthma and allergic diseases, and cancer, today ... to its board of directors. "Yujiro,s ... a tremendous asset to our board," said Bassil ... Xencor. "Xencor faces a range of opportunities for our ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Conn., Oct. 6 The Hedgeye Risk Management Healthcare team, led ... Conference Call, "Aging of America: Demographics of Demand and Profits in ... long tail of demographics, why 1994-2002 was so good, and why ... device demand, and the outlook for hip, knee, and spine device ...
... Oct. 6 Roxane Laboratories, Inc. announced today ... (ANDA) for Losartan Potassium Tablets USP, 25mg, 50mg ... Hydrochlorothiazide Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. ... for immediate shipment to wholesalers and pharmacies nationwide. ...
Cached Medicine Technology:Aging of America: Demographics of Demand and Profits in Healthcare 2Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets 2
(Date:7/31/2015)... ... 31, 2015 , ... “Engage: Don’t Just Age” will be ... leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International at Foxwoods Resort Casino ... “C”-level executives, administrators, directors of nursing, rehabilitation managers and other management and corporate ...
(Date:7/31/2015)... ... 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based ... BioViva announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use ... cure. MaxLife will grant 100% of the money raised to BioViva to help bring ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor ... out of the window, he recalled that his equipment was set up to depict the ... he jumped out of bed. , The photo speaks for itself. Chatfield is also a ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Awarded to only ... is proud to announce that they are the latest recipients of the Center ... status as one of the worldwide leaders in the science of hair transplant. , ...
(Date:7/31/2015)... ... 2015 , ... Eldermark Software, the innovative leader of senior ... Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is a compilation of three ... of using medication management technologies . , Eldermark’s case study ...
Breaking Medicine News(10 mins):Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... CEO: "This Deal Places IDE in a Key Position for ... Presence on the Australian ... TEL AVIV, Israel, August 12 IDE Technologies, jointly,owned ... Delek Group, signed a contract to supply a desalination plant ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) ("Duska") announced today ... Drug Administration,s (the "FDA"),Division of Cardiovascular and Renal Products ... with its lead drug, ATPace(TM), for the acute,treatment of ... On April 16, 2008, Duska met with the FDA ...
... distress to improve quality of life , , TUESDAY, ... increased risk for suicide, according to three new studies. ... of Washington analyzed U.S. data from 1973 to 2002 ... was 31.4 per 100,000 person-years, compared to 16.7 per ...
... MOUNTAIN VIEW, Calif., Aug. 12 MAP,Pharmaceuticals, Inc. (Nasdaq: ... June 30, 2008., The net loss for the second ... million during the same period in 2007. The net,loss for ... to $15.3,million for the first six months of 2007. As ...
... Texas, Aug. 12 American,HealthChoice, Inc. (Pink Sheets: ... clinics in Texas and Tennessee, is pleased to ... Scan, an infrared thermal imaging camera,that will be ... human body.,In conjunction with existing technologies, the OmniBody ...
... is celebrating the opening their latest location in Anderson ... services in the senior home care area. Preferred Care ... Alabama, Missouri and Minnesota. Of interest too, is that ... Anyone who has a desire to make a difference ...
Cached Medicine News:Health News:IDE Technologies Signs Contract Worth Over 100 Million Euros to Supply a Desalination Plant to Australia 2Health News:Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis 2Health News:Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis 3Health News:Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis 4Health News:Older Patients With Cancer at Heightened Suicide Risk 2Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 2Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 3Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 4Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 5Health News:MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results 6Health News:American HealthChoice Announces Launch of OmniBody Scan 2Health News:American HealthChoice Announces Launch of OmniBody Scan 3Health News:Senior Home care Providers keep Expanding Throughout the US 2Health News:Senior Home care Providers keep Expanding Throughout the US 3
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
CranioFix2 is the next generation CranioFix Titanium Clamp System, which is up to 40% faster than the original CranioFix and all flap fixation systems on the market....
... is an accurate, reliable, portable, and ... It works off of a dual-rechargeable ... the device a breeze. The large, ... operating and viewing results simple. Built ...
Medicine Products: